Zai Lab Ltd ADR (ZLAB) Stock Price, Quote & News

Company Profile

Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for commu...

Industry: Biotechnology

Sector: Healthcare

Phone: 86 21 6163 2588

Website: www.zailaboratory.com

Address:

Building B, 899 Halei Road, Pudong, China

BillionerOfKing Feb. 23 at 9:41 PM

$ZLAB Current Stock Price: $19.72 Contracts to trade: $20.0 ZLAB Mar 20 2026 Call Entry: $1.25 Exit: $1.98 ROI: 58% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

lightbutterfly Feb. 19 at 9:06 PM

$ZLAB this thing is resisting downward pressure !!! might signal a good rally ?

0 · Reply

Spartrap Feb. 18 at 10:16 AM

$ZLAB no HK trading Feb 17-19

0 · Reply

Zaksab Feb. 13 at 3:01 PM

$ZLAB In. So unloved. Kobenify should be a good un.

0 · Reply

Tdorsey1776 Feb. 12 at 1:57 PM

$ZLAB https://ir.zailaboratory.com/news-releases/news-release-details/us-fda-approves-novocures-optune-paxr-treatment-locally-advanced

0 · Reply

Tdorsey1776 Feb. 12 at 2:29 AM

$ZLAB Whats the TAM for TTFs+ in pancreatic in China? Worth a few bucks

0 · Reply

Tdorsey1776 Feb. 12 at 12:48 AM

$ZLAB Should see a bump with the Novocure FDA approval in pancreatic.... Novocure Stock Surges on FDA Approval for Optune Pax - WSJ https://share.google/LTvbZWr86eJJLDE6E

0 · Reply

topstockalerts Feb. 10 at 7:36 PM

$ZLAB Making a move as buyers step in. Price is starting to break away from the range. Momentum is clearly shifting.

0 · Reply

AJ6868 Feb. 10 at 7:25 PM

$ZLAB time to rip

0 · Reply

_TP888 Feb. 10 at 6:51 PM

$ZLAB | $20.00 | Call | Premium: $147,680

0 · Reply

Baron Emerging Markets Fund Q4 2025 Portfolio Activity

2026-02-21T00:55:48.000Z - 3 days ago

RTW INVESTMENTS, LP's Strategic Acquisition of Zai Lab Ltd Shares

2026-02-20T21:44:57.000Z - 3 days ago

Zai Lab Limited (ZLAB) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript

Tue, 10 Feb 2026 08:30:00 -0500 - 14 days ago

Zai Lab to Announce Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates on February 26, 2026

2026-02-03T11:23:52.000Z - 21 days ago

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Quarter

Tue, 03 Feb 2026 06:23:52 -0500 - 21 days ago

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Quarter

2026-01-15T23:05:53.000Z - 5 weeks ago

Zai Lab Limited (ZLAB) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow

2026-01-14T04:00:07.000Z - 5 weeks ago

Zai Lab Ltd at JPMorgan Healthcare Conference Transcript

2026-01-14T03:15:57.000Z - 5 weeks ago

Zai Lab Limited (ZLAB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Tue, 13 Jan 2026 08:00:00 -0500 - 6 weeks ago

Zai Lab Highlights Strategic Priorities and Global Pipeline Progress at 44th Annual J.P. Morgan Healthcare Conference

Tue, 06 Jan 2026 07:30:00 -0500 - 7 weeks ago

Zai Lab Announces National Medical Products Administration (NMPA) Approval of AUGTYRO™ (repotrectinib) for Patients with NTRK-Positive Solid Tumors

Mon, 05 Jan 2026 07:30:00 -0500 - 7 weeks ago

Zai Lab to Present at 44th Annual J.P. Morgan Healthcare Conference

2026-01-05T03:16:43.000Z - 7 weeks ago

After-Hours Gainers: GH Research, Phathom, Forte, OKYO, Zai Lab, LifeMD, Werewolf & Corvus Rally

2025-12-24T00:23:44.000Z - 2 months ago

Zai Lab Receives Approval In China For Schizophrenia Drug COBENFY

2025-12-23T14:26:05.000Z - 2 months ago

Zai Lab Secures China's Approval For Schizophrenia Therapy In Adults

Tue, 23 Dec 2025 07:30:00 -0500 - 2 months ago

Zai Lab Announces Approval of COBENFY (xanomeline and trospium chloride) in China, a First-in-Class Therapy for Schizophrenia

2025-12-19T00:05:12.000Z - 2 months ago

Insider Sell: Edmondson Frazor Titus III Sells 8,651 Shares of Zai Lab Ltd (ZLAB)

Mon, 08 Dec 2025 07:00:00 -0500 - 2 months ago

Zai Lab Announces Dosing of First Participant in Global Phase 1/1b study of ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis

2025-12-07T18:31:13.000Z - 2 months ago

Zai Lab (ZLAB) Secures Renewal for Key Drugs in China's 2025 NRDL

Sun, 07 Dec 2025 00:11:00 -0500 - 2 months ago

Zai Lab Announces Updates to China's National Reimbursement Drug List

2025-11-15T02:07:45.000Z - 3 months ago

Wellington Management Group LLP's Strategic Acquisition in Zai Lab Ltd

2025-11-12T23:03:42.000Z - 3 months ago

Zai Lab Limited 2025 Q3 - Results - Earnings Call Presentation

2025-11-11T17:00:38.000Z - 3 months ago

Zai Lab Limited: Declining Despite Making Progress - I See Opportunity (Reiterate Buy)

2025-11-07T13:16:06.000Z - 3 months ago

Zai Lab Limited (ZLAB) Q3 2025 Earnings Call Transcript

2025-11-07T05:07:24.000Z - 3 months ago

Decoding Zai Lab Ltd (ZLAB): A Strategic SWOT Insight

2025-11-06T19:08:00.000Z - 3 months ago

Zai Lab Ltd (ZLAB) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amid Market Challenges

2025-11-06T18:21:05.000Z - 3 months ago

Q3 2025 Zai Lab Ltd Earnings Call Transcript

2025-11-06T12:33:51.000Z - 3 months ago

Zai Lab Ltd (ZLAB) Q3 2025 Earnings: EPS Loss of $0.03 Beats Estimates, Revenue of $116. ...

Thu, 06 Nov 2025 07:00:00 -0500 - 3 months ago

Zai Lab Announces Third Quarter 2025 Financial Results and Recent Corporate Updates

2025-11-05T19:01:15.000Z - 3 months ago

Zai Lab Q3 2025 Earnings Preview

2025-11-05T17:42:13.000Z - 3 months ago

Zai Lab is Now Oversold (ZLAB)

2025-11-03T11:25:27.000Z - 4 months ago

ZLAB: Goldman Sachs Removes Zai Lab from APAC Conviction List

Fri, 31 Oct 2025 07:30:00 -0400 - 4 months ago

Zai Lab Announces Participation in Investor Conferences in November and December 2025

2025-10-27T05:49:32.000Z - 4 months ago

Zai Lab Limited (ZLAB) Discusses Updated Monotherapy Phase I Data for Zoci and Outlines Next Steps in Clinical Development Transcript

2025-10-24T18:37:37.000Z - 4 months ago

Zai Lab Limited (ZLAB) Discusses Updated Monotherapy Phase I Data for Suzhou and Outlines Next Steps in Clinical Development Transcript

2025-10-24T16:48:18.000Z - 4 months ago

Zai Lab Limited (ZLAB) Discusses Updated Monotherapy Phase I Data for Suzhou and Outlines Next Steps in Clinical Development - Slideshow

Fri, 24 Oct 2025 09:00:00 -0400 - 4 months ago

Zai Lab Announces Updated Phase 1 Data for Zocilurtatug Pelitecan (formerly ZL-1310), Demonstrating Potential as a First-in-Class/Best-in-Class DLL3-Targeted ADC for Small Cell Lung Cancer, and Initiation of Global Phase 3 Registrational Study

Wed, 15 Oct 2025 07:30:00 -0400 - 4 months ago

Zai Lab to Announce Third Quarter 2025 Financial Results and Recent Corporate Updates on November 6, 2025

2025-10-14T17:28:00.000Z - 4 months ago

Zai Lab (ZLAB) Stock Declines Nearly 7%

Mon, 13 Oct 2025 12:02:00 -0400 - 4 months ago

Zai Lab Announces Oral Presentation of Updated Data from Global Phase 1 Trial of Zocilurtatug Pelitecan (ZL-1310), a Potential First-in-Class DLL3-Targeted ADC, at 2025 AACR-NCI-EORTC Conference

2025-09-11T12:02:01.000Z - 5 months ago

Zai Lab's Double Whammy: Earnings Miss, Phase 3 Setback

Thu, 11 Sep 2025 08:02:01 -0400 - 5 months ago

Zai Lab's Double Whammy: Earnings Miss, Phase 3 Setback

2025-09-10T19:55:58.000Z - 5 months ago

China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order

2025-09-09T22:47:49.000Z - 5 months ago

Zai Lab Limited (ZLAB) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sat, 06 Sep 2025 10:00:00 -0400 - 6 months ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zai Lab Limited - ZLAB

2025-09-03T15:35:50.000Z - 6 months ago

Amgen dips after trial update for Zai Lab partnered gastric cancer therapy

2025-09-02T02:00:54.000Z - 6 months ago

Zai Lab Ltd (ZLAB) Secures Approval for TIVDAK in Hong Kong | ZLAB stock news

2025-09-02T01:15:07.000Z - 6 months ago

Zai Lab Announces Approval of TIVDAKÂ® for Patients with Recurrent or Metastatic Cervical ...

Mon, 01 Sep 2025 20:00:00 -0400 - 6 months ago

Zai Lab Announces Approval of TIVDAK® for Patients with Recurrent or Metastatic Cervical Cancer in Hong Kong

Thu, 28 Aug 2025 07:30:00 -0400 - 6 months ago

Zai Lab Announces Participation in Investor Conferences in September 2025

Aug 19, 2025, 7:30 AM EDT - 6 months ago

Zai Lab Announces China National Medical Products Administration Grants Innovative Medical Device Designation for Tumor Treating Fields for Patients with Pancreatic Cancer

Aug 13, 2025, 11:00 AM EDT - 6 months ago

Zai Lab Establishes Oncology Scientific Advisory Board

Aug 7, 2025, 10:29 PM EDT - 7 months ago

Zai Lab Limited (ZLAB) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 6:00 AM EDT - 7 months ago

Zai Lab Announces Second Quarter 2025 Financial Results and Recent Corporate Updates

Jul 10, 2025, 7:30 AM EDT - 8 months ago

Zai Lab to Announce Second Quarter 2025 Financial Results and Recent Corporate Updates on August 7, 2025

Jun 30, 2025, 9:05 AM EDT - 8 months ago

Zai Lab Announces Positive Topline Phase 3 Results for Bemarituzumab in Fibroblast Growth Factor Receptor 2b (FGFR2b) Positive First-Line Gastric Cancer

Jun 13, 2025, 7:00 AM EDT - 9 months ago

Zai Lab Presents New Preclinical Data for ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis, at EAACI Congress 2025

Jun 2, 2025, 7:00 AM EDT - 9 months ago

Zai Lab Presents Positive Phase 1 Data for ZL-1310, a DLL3-Targeted ADC, Demonstrating Robust Anti-Tumor Activity and Safety in Patients with Extensive-Stage Small Cell Lung Cancer at 2025 ASCO Annual Meeting

May 31, 2025, 3:08 PM EDT - 9 months ago

Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

NVCR

May 30, 2025, 7:30 AM EDT - 9 months ago

Zai Lab Announces Participation in Investor Conferences in June 2025

May 28, 2025, 2:48 AM EDT - 9 months ago

Zai Lab Limited Is Well Positioned For Long-Term Growth

May 22, 2025, 11:25 AM EDT - 9 months ago

Zai Lab Limited: Banking On Chinese Pharma Growth

May 19, 2025, 7:00 AM EDT - 10 months ago

Zai Lab Receives U.S. FDA Fast Track Designation for ZL-1310, a DLL3-Targeted Antibody-Drug Conjugate, for Treatment of Extensive-Stage Small Cell Lung Cancer

May 11, 2025, 8:55 AM EDT - 10 months ago

Zai Lab Limited (ZLAB) Q1 2025 Earnings Call Transcript

May 8, 2025, 6:00 AM EDT - 10 months ago

Zai Lab Announces First Quarter 2025 Financial Results and Recent Corporate Updates

Apr 25, 2025, 1:12 PM EDT - 10 months ago

Zai Lab Presents Data Highlighting Potential of Internally Developed, Next-Generation Oncology Therapies at AACR 2025

Apr 23, 2025, 10:56 AM EDT - 10 months ago

Zai Lab to Present Data from Phase 1 Trial of DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310 at 2025 ASCO Annual Meeting

Apr 21, 2025, 7:30 AM EDT - 11 months ago

Zai Lab Announces Acceptance of Supplemental New Drug Application for Repotrectinib for Patients with NTRK-Positive Solid Tumors

Mar 26, 2025, 7:00 AM EDT - 11 months ago

Zai Lab to Present New Data from Internally Developed, Next-Generation Oncology Candidates at AACR 2025 Annual Meeting

Mar 21, 2025, 5:16 PM EDT - 1 year ago

Zai Lab: Innovative Pharma Set For Strong Year Of Business (And Share Price) Growth

Mar 20, 2025, 1:05 PM EDT - 1 year ago

Zai Lab: Still Attractive Despite Higher Costs And Added Trade War Risks

Mar 12, 2025, 7:30 PM EDT - 1 year ago

Zai Lab Announces Acceptance of Biologics License Application for TIVDAK for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer

Mar 3, 2025, 7:30 AM EST - 1 year ago

Zai Lab Announces Participation in Investor Conferences in March 2025

Feb 27, 2025, 10:46 PM EST - 1 year ago

Zai Lab Limited (ZLAB) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 6:00 AM EST - 1 year ago

Zai Lab Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Updates

Jan 28, 2025, 7:30 AM EST - 1 year ago

Zai Lab to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Recent Corporate Updates on February 27, 2025

BillionerOfKing Feb. 23 at 9:41 PM

0 · Reply

lightbutterfly Feb. 19 at 9:06 PM

$ZLAB this thing is resisting downward pressure !!! might signal a good rally ?

0 · Reply

Spartrap Feb. 18 at 10:16 AM

$ZLAB no HK trading Feb 17-19

0 · Reply

Zaksab Feb. 13 at 3:01 PM

$ZLAB In. So unloved. Kobenify should be a good un.

0 · Reply

Tdorsey1776 Feb. 12 at 1:57 PM

$ZLAB https://ir.zailaboratory.com/news-releases/news-release-details/us-fda-approves-novocures-optune-paxr-treatment-locally-advanced

0 · Reply

Tdorsey1776 Feb. 12 at 2:29 AM

$ZLAB Whats the TAM for TTFs+ in pancreatic in China? Worth a few bucks

0 · Reply

Tdorsey1776 Feb. 12 at 12:48 AM

$ZLAB Should see a bump with the Novocure FDA approval in pancreatic.... Novocure Stock Surges on FDA Approval for Optune Pax - WSJ https://share.google/LTvbZWr86eJJLDE6E

0 · Reply

topstockalerts Feb. 10 at 7:36 PM

$ZLAB Making a move as buyers step in. Price is starting to break away from the range. Momentum is clearly shifting.

0 · Reply

AJ6868 Feb. 10 at 7:25 PM

$ZLAB time to rip

0 · Reply

_TP888 Feb. 10 at 6:51 PM

$ZLAB | $20.00 | Call | Premium: $147,680

0 · Reply

pierke Feb. 9 at 3:38 PM

$ZLAB cheap

0 · Reply

Spartrap Feb. 9 at 12:03 PM

$ZLAB great improvement in the sino-american relationship in bio with the massive LLY-Innovent deal. Peace comes from complex interdependence of non-state actors as was developed by Kehoane & Nye. Make no mistake and load on ZLAB because the market will soon follow the lead

0 · Reply

StorageArbX Feb. 4 at 1:37 PM

$ZLAB is a Chinese biotech with innovative oncology and autoimmune drugs; its valuation bridges U.S. biotech multiples and China-specific regulatory and commercialization risks.

0 · Reply

vivek5959 Feb. 3 at 5:40 PM

@Pika_Capital would like to know your thoughts on $ZLAB near 52 week low .. thank you in advance🙏

1 · Reply

SodApOp_PIMPski_Rises Feb. 2 at 4:42 PM

$ZLAB continued 52week lows still printing.. watching from the sidelines until a bottom is found

0 · Reply

JacksonCapital Jan. 27 at 6:29 PM

$ZLAB Back in, this is HIGHLY undervalued

0 · Reply

AJ6868 Jan. 26 at 3:17 PM

$ZLAB just started position for bounce

0 · Reply

Spartrap Jan. 23 at 3:19 PM

$ZLAB I don't mind being the lone cheerleader here until this is trading at$400. Will happen much faster than you think.. Take it from someone who was buying AMD at$11 in 2018 😌

0 · Reply

OfficialStocktwitsUser Jan. 22 at 7:46 PM

$ZLAB RSI: 56.51, MACD: -0.1228 Vol: 0.58, MA20: 18.37, MA50: 19.07 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Spartrap Jan. 13 at 11:48 PM

$ZLAB Q&A session at JPM was crazy sharp. Analysts really starting to take notice

0 · Reply

Spartrap Jan. 13 at 4:09 PM

$ZLAB incredible pipeline. Look at the depth of it. This has to be one of the most deeply mispriced security in the entire market. After 8 years of analysing and investing in biotechs, it is the first time I actively recommend a name to my closest friends and family

0 · Reply

Spartrap Jan. 13 at 1:48 PM

$ZLAB https://ir.zailaboratory.com/news-releases/news-release-details/zai-lab-highlights-strategic-priorities-and-global-pipeline

0 · Reply

Market Cap	2.26B
Revenue (ttm)	398.99M
Net Income (ttm)	-257.10M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-64.44%
Debt to Equity Ratio	0.27

Volume	585,800
Avg Vol	782,432
Day's Range	N/A - N/A
Shares Out	112.81M
Stochastic %K	71%
Beta	0.88
Analysts	Strong Sell
Price Target	$42.92